0UNL Stock Overview A biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Nektar Therapeutics Competitors Price History & Performance
Summary of share price highs, lows and changes for Nektar Therapeutics Historical stock prices Current Share Price US$0.92 52 Week High US$1.93 52 Week Low US$0.50 Beta 0.59 1 Month Change 1.73% 3 Month Change -34.00% 1 Year Change 81.60% 3 Year Change -91.47% 5 Year Change -95.93% Change since IPO -98.06%
Recent News & Updates
CEO, President & Director recently sold US$132k worth of stock Dec 21
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting Dec 08 Ampersand Management LLC completed the acquisition of Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR). Dec 03
Insufficient new directors Dec 01
Nektar Therapeutics Provides Earnings Guidance for the Full Year of 2024 Nov 09
Third quarter 2024 earnings released: US$0.18 loss per share (vs US$0.24 loss in 3Q 2023) Nov 08 See more updates
CEO, President & Director recently sold US$132k worth of stock Dec 21
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting Dec 08 Ampersand Management LLC completed the acquisition of Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR). Dec 03
Insufficient new directors Dec 01
Nektar Therapeutics Provides Earnings Guidance for the Full Year of 2024 Nov 09
Third quarter 2024 earnings released: US$0.18 loss per share (vs US$0.24 loss in 3Q 2023) Nov 08
Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting Nov 08 Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR) for $90 million. Nov 06
Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR) for $90 million. Nov 05
New major risk - Revenue and earnings growth Nov 04
Nektar Therapeutics to Report Q3, 2024 Results on Nov 07, 2024 Nov 01
Nektar Therapeutics Announces Publication in Nature Communications of Results from Phase 1B Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases Oct 29
Nektar Therapeutics Announces Publication in Blood of Phase 1 Data for Novel II-15 Agonist NKTR-255 in Combination with Autologous CD19-22 Car-T Cell Therapy in Patients with B-Cell Acute Lymphoblastic Leukemia Oct 17
Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.27 loss in 2Q 2023) Aug 09
Nektar Therapeutics to Report Q2, 2024 Results on Aug 08, 2024 Aug 02
First quarter 2024 earnings released: US$0.19 loss per share (vs US$0.72 loss in 1Q 2023) May 13
Nektar Therapeutics to Report Q1, 2024 Results on May 09, 2024 May 03
Nektar Therapeutics, Annual General Meeting, Jun 05, 2024 Apr 28 Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC Mar 20
Full year 2023 earnings released: US$1.45 loss per share (vs US$1.97 loss in FY 2022) Mar 06
Nektar Therapeutics Announces Initiation of Phase 2B Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata Mar 05 Nektar Therapeutics announced that it expects to receive $30 million in funding from TCG Crossover Management, LLC Mar 04
Nektar Therapeutics to Report Q4, 2023 Results on Mar 04, 2024 Feb 27
New major risk - Share price stability Feb 07
Nasdaq States Nektar Therapeutics Eligible for an Additional 180 Calendar Day Period, or Until May 20, 2024, to Regain Compliance with the Minimum Bid Price Requirement Nov 29
Nasdaq States Nektar Therapeutics Eligible for an Additional 180 Calendar Day Period, or Until May 20, 2024, to Regain Compliance with the Minimum Bid Price Requirement Nov 28
Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.32 loss in 3Q 2022) Nov 09
Nektar Therapeutics to Report Q3, 2023 Results on Nov 07, 2023 Nov 01
Nektar Therapeutics Presents New Responder Data for Rezpegaldesleukin, A First-In-Class Selective Regulatory T-Cell Therapy Oct 14
New minor risk - Market cap size Oct 10
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate Nktr-255 in Combination with C-Til051 in Advanced Non-Small Cell Lung Cancer Sep 28
Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-To-Severe Atopic Dermatitis Sep 14
Second quarter 2023 earnings released: US$0.27 loss per share (vs US$0.85 loss in 2Q 2022) Aug 09
Nektar Therapeutics Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company Aug 08
Nektar Therapeutics to Report Q2, 2023 Results on Aug 08, 2023 Aug 03
New minor risk - Market cap size Jul 25
Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 2000 Index Jun 25
New minor risk - Market cap size Jun 22
Nektar Therapeutics Receives Notice from The Nasdaq Global Select Market Due to Non-Compliance with the Minimum Bid Price Rule Jun 03
First quarter 2023 earnings released: US$0.72 loss per share (vs US$0.49 loss in 1Q 2022) May 10
Nektar Therapeutics Reports Impairment of Goodwill for the First Quarter Ended March 31, 2023 May 10
Full year 2022 earnings released: US$1.97 loss per share (vs US$2.86 loss in FY 2021) Mar 01
CEO, President & Director recently sold US$59k worth of stock Feb 23
Insufficient new directors Jan 01
CEO, President & Director recently sold US$136k worth of stock Nov 20
Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, A Novel Polymer-Conjugated Human IL-15, Improves Efficacy of CD19-Targeted CAR-T Cell Immunotherapy Nov 10
Third quarter 2022 earnings released: US$0.32 loss per share (vs US$0.70 loss in 3Q 2021) Nov 05
Nektar Therapeutics to Report Q3, 2022 Results on Nov 03, 2022 Oct 26
Nektar Therapeutics (NasdaqGS:NKTR) submitted a non-binding proposal to acquire PureTech Health plc (LSE:PRTC). Oct 08
Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (Eadv) Congress Sep 07
CEO, President & Director recently sold US$65k worth of stock Aug 20
Nektar Therapeutics Announces Preclinical Publication of Data for NKTR-255 and Its Observed Improvement of NK Cell Function in Multiple Myeloma Aug 17
Second quarter 2022 earnings released: US$0.85 loss per share (vs US$0.69 loss in 2Q 2021) Aug 05
Nektar Therapeutics Provides Earnings Guidance for the Year 2022 Aug 05
Nektar Therapeutics to Report Q2, 2022 Results on Aug 04, 2022 Jul 28 Nektar Promotes Jillian B. Thomsen to Senior Vice President
Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 1000 Dynamic Index Jun 26
Nektar Therapeutics Reviews Interim Efficacy and Safety Data from the Ongoing Phase 2 Double Blinded, Placebo-Controlled Study May 24
CEO, President & Director recently sold US$144k worth of stock May 20
First quarter 2022 earnings released: US$0.49 loss per share (vs US$0.68 loss in 1Q 2021) May 06
Nektar Therapeutics, Annual General Meeting, Jun 08, 2022 May 02
John Northcott Step Down as Senior Vice President and Chief Commercial Officer of Nektar Therapeutics Apr 26
Nektar Therapeutics and Bristol-Myers Squibb Company Announce Update on Clinical Development Program for Bempegaldesleukin (Bempeg) in Combination with Opdivo (Nivolumab) Apr 16
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 02
Nektar Therapeutics Provides Revenue Guidance for the Full Year 2022 Mar 02
Chief Research & Development Officer recently sold US$119k worth of stock Feb 19
Nektar Therapeutics to Report Q4, 2021 Results on Feb 28, 2022 Feb 18
Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, At the 63Rd American Society of Hematology (ASH) Annual Meeting Dec 14
Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Programs At the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021 and the 63rd American Society of Hematology (ASH) Annual Meeting Dec 01
Senior VP recently sold US$278k worth of stock Nov 19
Third quarter 2021 earnings released: US$0.70 loss per share (vs US$0.61 loss in 3Q 2020) Nov 06
Insider recently sold US$65k worth of stock Sep 26
Redhill Biopharma Inc., AstraZeneca AB and AstraZeneca Pharmaceuticals LP and Nektar Therapeutics Enters into A Settlement and License Agreement with Aurobindo Pharma USA, Inc Sep 24
Insider recently sold US$184k worth of stock Aug 19
Second quarter 2021 earnings released: US$0.69 loss per share (vs US$0.45 loss in 2Q 2020) Aug 08
RedHill Biopharma Inc., Astrazeneca AB and Astrazeneca Pharmaceuticals LP and Nektar Therapeutics Enters into Settlement and License Agreement with Apotex, Inc. and Apotex Corp. Resolving Their Patent Litigation in the U.S Jul 24
Nektar Therapeutics Announces First Publication of NKTR-358, a Novel Molecule Designed to Selectively Stimulate Expansion and Selective Function of T Regulatory Cells, in the Journal of Translational Autoimmunity May 21
Chief Research & Development Officer recently sold US$569k worth of stock May 20
Nektar Therapeutics Announces its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC) May 19
Nektar Therapeutics Provides Revenue Guidance for the Full Year of 2021 May 08
First quarter 2021 earnings released: US$0.68 loss per share (vs US$0.78 loss in 1Q 2020) May 08
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with MSN Pharmaceuticals Mar 26
Revenue misses expectations Feb 27
Full year 2020 earnings released: US$2.49 loss per share (vs US$2.52 loss in FY 2019) Feb 27
Biolojic Design, Ltd. Enters A Research Collaboration and License Option Agreement with Nektar Therapeutics to Develop Computationally Designed Antibodies Against A Novel Target for the Potential Treatment of Autoimmune Disease Feb 26
Chief Research & Development Officer recently sold US$540k worth of stock Feb 19 Shareholder Returns 0UNL GB Pharmaceuticals GB Market 7D 0.08% 0.3% 3.5% 1Y 81.6% -2.0% 10.5%
See full shareholder returns
Return vs Market: 0UNL exceeded the UK Market which returned 10.5% over the past year.
Price Volatility Is 0UNL's price volatile compared to industry and market? 0UNL volatility 0UNL Average Weekly Movement 10.2% Pharmaceuticals Industry Average Movement 6.7% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.9% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0UNL's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0UNL's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer. The company serves its clients in the United States and internationally.
Show more Nektar Therapeutics Fundamentals Summary How do Nektar Therapeutics's earnings and revenue compare to its market cap? 0UNL fundamental statistics Market cap US$164.54m Earnings (TTM ) -US$168.30m Revenue (TTM ) US$93.14m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0UNL income statement (TTM ) Revenue US$93.14m Cost of Revenue US$29.99m Gross Profit US$63.15m Other Expenses US$231.45m Earnings -US$168.30m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.91 Gross Margin 67.80% Net Profit Margin -180.70% Debt/Equity Ratio 200.1%
How did 0UNL perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/21 21:25 End of Day Share Price 2025/01/21 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Nektar Therapeutics is covered by 34 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Richard Silver Barclays Aydin Huseynov Benchmark Company George Farmer BMO Capital Markets Equity Research
Show 31 more analysts 
